Triplex Pharmaceutical Corp. announced that it has entered intoa research collaboration with Wistar Institute researcher EvaGonczol to evaluate and characterize the activity of Triplex'soligonucleotide compounds against human cytomegalovirus(CMV).

Scientists at privately held Triplex of The Woodlands, Texas,have already identified several oligonucleotides that havesignificant in vitro activity against CMV. Together with Gonczol,who is an expert on CMV, they hope to evaluate thosecompounds for in vivo studies leading to clinical trials.

(c) 1997 American Health Consultants. All rights reserved.